• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Polyrizon Ltd.

    6/30/25 4:15:29 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRZ alert in real time by email
    6-K 1 ea0247119-6k_polyrizon.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of June 2025

     

    Commission file number: 001-42375

     

    Polyrizon Ltd.

    (Translation of registrant’s name into English)

     

    5 Ha-Tidhar Street

    Raanana, 4366507, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

      

     

     

     

     

     

    CONTENTS

     

    On June 25, 2025, Mr. Omer Srugo, a member of the Board of Directors of Polyrizon Ltd. (the “Board” and the “Company”, respectively), tendered his resignation from the Board, effective immediately. Mr. Srugo’s resignation from the Board was not due to any disagreement with the Company, the Board or the Company’s management on any matter relating to the Company’s operations, policies, practices or otherwise.

     

    In addition, the Board has determined the following members of the Board to be “independent” in accordance with the listing rules of the Nasdaq Stock Market: Asaf Itzhaik, Liat Sidi, Yehonatan Zalman Vinokur and Liron Carmel.

     

    This Form 6-K is incorporated by reference into the Registrant’s Registration Statement on Form S-8 (File No. 333-284410), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Polyrizon Ltd.
       
    Date: June 30, 2025 By: /s/ Tomer Izraeli
      Name:  Tomer Izraeli
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $PLRZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLRZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLRZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

    Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into a development agreement with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind"), a clinical‑stage biopharmaceutical company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems. Under this agreement, Polyr

    2/6/26 7:55:00 AM ET
    $CMND
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

    Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind's lead MEAI candidate for addiction-related and other CNS disorders Vancouver, Canada, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a development agreement with Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon"), a pre-clinical-stage biotechnology company developing advanced intranasal delivery solutions. Under the agreement, Clear

    2/6/26 7:55:00 AM ET
    $CMND
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

    The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. ("Arrow Aviation"), a global private aviation company. Under the terms of the MOU, Polyrizon intends to acquire a 51% stake in Arrow Aviation on a fully diluted basis through a cash inves

    2/4/26 7:12:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    SEC Filings

    View All

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    2/6/26 7:58:22 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    2/4/26 7:13:23 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    1/22/26 9:28:20 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    Leadership Updates

    Live Leadership Updates

    View All

    Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

    Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

    12/19/24 7:22:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

    Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

    12/13/24 6:25:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care